ARS Pharmaceuticals (SPRY) Amortization of Deferred Charges (2020 - 2022)
ARS Pharmaceuticals (SPRY) reported Amortization of Deferred Charges of $40000.0 for Q3 2022, up 107.1% on a YoY basis from $19313.9 in Q3 2021, and up 124.39% sequentially from -$164000.0 in Q2 2022.
ARS Pharmaceuticals (SPRY) Amortization of Deferred Charges (2020 - 2022) Analysis & Trends
ARS Pharmaceuticals (SPRY) has 3 years of Amortization of Deferred Charges data on file, last reported at $40000.0 in Q3 2022.
- For the quarter ending Q3 2022, Amortization of Deferred Charges rose 107.1% year-over-year to $40000.0; the trailing twelve-month figure through Sep 2023 stood at $125000.0 (down 90.15% YoY), and the FY2021 full-year result was $1.1 million, up 3596.77% from the prior year.
- Amortization of Deferred Charges grew to $40000.0 in Q3 2022, from -$164000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $1.1 million in Q4 2021 to a low of -$563000.0 in Q3 2021.
- A 3-year average of $118363.6 and a median of $249000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- Across the five-year window, Amortization of Deferred Charges jumped 38033.33% in 2021 and sank 157.54% in 2022, its largest moves.
- Tracing SPRY's Amortization of Deferred Charges over 3 years: stood at $3000.0 in 2020, then jumped by 38033.33% to $1.1 million in 2021, then slumped by 96.5% to $40000.0 in 2022.
- Business Quant data shows SPRY's Amortization of Deferred Charges at $40000.0 in Q3 2022, -$164000.0 in Q2 2022, and $249000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn |
| 10 | ARS Pharmaceuticals | 572.93 Mn | 371.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 40,000.00 |
| Sep 30, 2022 | 40,000.00 |
| Jun 30, 2022 | -164,000.00 |
| Jun 30, 2022 | -164,000.00 |
| Mar 31, 2022 | 249,000.00 |
| Mar 31, 2022 | 249,000.00 |
| Dec 31, 2021 | 1.14 Mn |
| Dec 31, 2021 | 1.14 Mn |
| Sep 30, 2021 | -563,000.00 |
| Sep 30, 2021 | -563,000.00 |
| Jun 30, 2021 | 285,000.00 |
| Jun 30, 2021 | 285,000.00 |
| Mar 31, 2021 | 280,000.00 |
| Mar 31, 2021 | 280,000.00 |
| Dec 31, 2020 | 3,000.00 |
| Dec 31, 2020 | 3,000.00 |
| Sep 30, 2020 | -499,000.00 |
| Sep 30, 2020 | -499,000.00 |
| Jun 30, 2020 | 265,000.00 |
| Jun 30, 2020 | 265,000.00 |